Ovarian Cancer Treatment Named Breakthrough Therapy with Potential in Advanced Prostate Cancers

Ovarian Cancer Treatment Named Breakthrough Therapy with Potential in Advanced Prostate Cancers
An approved therapy for advanced ovarian cancer — Rubraca (rucaparib) by Clovis Oncology — has been designated a  breakthrough therapy  by the U.S. Food and Drug Administration as a potential treatment for metastatic castration-resistant prostate cancer (mCRPC) patients with BRCA mutations. This FDA designation is given to speed the development of medications that might treat serious conditions and potentially provide an

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *